We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
+7.39%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$7.43B
AUM Growth
+$757M
Cap. Flow
+$285M
Cap. Flow %
3.83%
Top 10 Hldgs %
21.69%
Holding
281
New
28
Increased
104
Reduced
67
Closed
44

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$124M
2
MDT icon
Medtronic
MDT
+$67.1M
3
BDX icon
Becton Dickinson
BDX
+$51.8M
4
RTX icon
RTX Corp
RTX
+$51.1M
5
HUM icon
Humana
HUM
+$44.2M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$82.1M
2
BAX icon
Baxter International
BAX
+$49.3M
3
INCY icon
Incyte
INCY
+$42.4M
4
SYK icon
Stryker
SYK
+$34.6M
5
MD icon
Pediatrix Medical
MD
+$33.9M

Sector Composition

Rank Sector Weight
1 Financials 23.39%
2 Healthcare 23.32%
3 Technology 19.99%
4 Communication Services 10.16%
5 Industrials 7.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESV
226
DELISTED
Ensco Rowan plc
ESV
$549K 0.01%
+26,610
New +$764K
A icon
227
Agilent Technologies
A
$39.1B
– –
-420,500
Closed -$22.2M
ABBV icon
228
AbbVie
ABBV
$458B
– –
-80,000
Closed -$5.21M
AEM icon
229
Agnico Eagle Mines
AEM
$72.6B
– –
-121,369
Closed -$5.13M
AKAM icon
230
Akamai
AKAM
$16.8B
– –
-91,177
Closed -$5.44M
BAX icon
231
Baxter International
BAX
$11.6B
– –
-951,223
Closed -$49.3M
BLUE
232
DELISTED
bluebird bio
BLUE
– –
-1,544
Closed -$1.82M
BMY icon
233
Bristol-Myers Squibb
BMY
$127B
– –
-190,000
Closed -$10.3M
CSCO icon
234
Cisco
CSCO
$450B
– –
-502,934
Closed -$17M
DHC
235
Diversified Healthcare Trust
DHC
$2.26B
– –
-100,000
Closed -$2.02M
DOC icon
236
Healthpeak Properties
DOC
$15.4B
– –
-100,000
Closed -$3.13M
HAE icon
237
Haemonetics
HAE
$3.58B
– –
-474,024
Closed -$19.2M
HCSG icon
238
Healthcare Services Group
HCSG
$1.56B
– –
-38,372
Closed -$1.65M
HIMX
239
Himax Technologies
HIMX
$2.2B
– –
-364,618
Closed -$3.32M
HL icon
240
Hecla Mining
HL
$10.2B
– –
-863,162
Closed -$4.47M
ISRG icon
241
Intuitive Surgical
ISRG
$121B
– –
-235,206
Closed -$20M
MCK icon
242
McKesson
MCK
$98.5B
– –
-68,657
Closed -$10.2M
MD icon
243
Pediatrix Medical
MD
$2.16B
– –
-488,472
Closed -$33.9M
MPT
244
Medical Properties Trust
MPT
$2.89B
– –
-220,000
Closed -$2.83M
NBIX icon
245
Neurocrine Biosciences
NBIX
$17.7B
– –
-185,000
Closed -$8.01M
NGD
246
DELISTED
New Gold Inc
NGD
– –
-1,165,212
Closed -$3.55M
NHI icon
247
National Health Investors
NHI
$3.9B
– –
-25,000
Closed -$1.81M
OHI icon
248
Omega Healthcare
OHI
$15.4B
– –
-50,000
Closed -$1.65M
PI icon
249
Impinj
PI
$3.89B
– –
-85,280
Closed -$2.58M
PRTA icon
250
Prothena Corp
PRTA
$458M
– –
-30,000
Closed -$1.67M
7 8 9
10
11

Similar funds

ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Polar Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Polar Capital held 281 positions worth $7.43B, up 11% from $6.67B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Polar Capital deployed $285M of net new capital in Q2 2017, opening 28 new positions and adding to 104 existing holdings. Its largest new stake was RTX Corp: 681,946 shares worth $52.4M.

By sector, the portfolio is most concentrated in Financials at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Merck, an estimated $82.1M trimmed.

  • Polar Capital's largest Q2 2017 buy was RTX Corp: 681,946 shares worth $52.4M.
  • Polar Capital added most to Johnson & Johnson in Q2 2017, an estimated $124M increase.
  • Polar Capital's biggest Q2 2017 reduction was Merck, cutting an estimated $82.1M.
  • Polar Capital fully exited Baxter International in Q2 2017, selling an estimated $49.3M.
  • Polar Capital's ten largest holdings make up 22% of its $7.43B portfolio in Q2 2017.
  • Polar Capital opened 28 new positions and closed 44 in Q2 2017.
  • Polar Capital's portfolio value rose 11% quarter-over-quarter to $7.43B.

Based on Polar Capital's 13F filing for Q2 2017, filed 14 Aug 2017.